Last reviewed · How we verify

Albiglutide Lyophilized DCC Pen Injector

GlaxoSmithKline · Phase 1 active Small molecule

Albiglutide Lyophilized DCC Pen Injector is a GLP-1 receptor agonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development for Type 2 diabetes.

GLP-1 receptor agonist

GLP-1 receptor agonist Used for Type 2 diabetes.

At a glance

Generic nameAlbiglutide Lyophilized DCC Pen Injector
SponsorGlaxoSmithKline
Drug classGLP-1 receptor agonist
TargetGLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 1

Mechanism of action

Albiglutide is a long-acting GLP-1 receptor agonist that mimics the action of the incretin hormone glucagon-like peptide-1 (GLP-1) to regulate glucose metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Albiglutide Lyophilized DCC Pen Injector

What is Albiglutide Lyophilized DCC Pen Injector?

Albiglutide Lyophilized DCC Pen Injector is a GLP-1 receptor agonist drug developed by GlaxoSmithKline, indicated for Type 2 diabetes.

How does Albiglutide Lyophilized DCC Pen Injector work?

GLP-1 receptor agonist

What is Albiglutide Lyophilized DCC Pen Injector used for?

Albiglutide Lyophilized DCC Pen Injector is indicated for Type 2 diabetes.

Who makes Albiglutide Lyophilized DCC Pen Injector?

Albiglutide Lyophilized DCC Pen Injector is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Albiglutide Lyophilized DCC Pen Injector in?

Albiglutide Lyophilized DCC Pen Injector belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is Albiglutide Lyophilized DCC Pen Injector in?

Albiglutide Lyophilized DCC Pen Injector is in Phase 1.

What are the side effects of Albiglutide Lyophilized DCC Pen Injector?

Common side effects of Albiglutide Lyophilized DCC Pen Injector include Nausea, Vomiting, Diarrhea.

What does Albiglutide Lyophilized DCC Pen Injector target?

Albiglutide Lyophilized DCC Pen Injector targets GLP-1R and is a GLP-1 receptor agonist.

Related